The release of caspase-cleaved and total keratin 18 (ccK18 and K18, respectively) to serum has been well documented in clinical studies after treatment of breast and prostate cancer patients with cytotoxic drugs [13], [14], [15]. The gene discussed is KRT18; the disease is prostate carcinoma.